Deferasirox Fe3+ Chelate: Research Guide

Executive Summary: Deferasirox Fe3+ chelate is identified as 4-[3,5-bis(2-oxidophenyl)-1,2,4-triazol-1-yl]benzoate;iron(3+), with CAS 554435-83-5 and a molecular weight of 426.18 g/mol, according to the A3355 product information. The material is supplied at 98.00% purity and is intended for scientific research rather than diagnosis or treatment, as specified by the originating company APExBIO. The product information reports solubility of at least 53.5 mg/mL in DMSO and at least 12.68 mg/mL in ethanol under vendor-reported conditions that are not further specified, while describing the compound as insoluble in water. The peer-reviewed reference study found that uncomplexed deferasirox produces differentiation-stage-dependent changes in mitochondrial reactive oxygen species and NF-κB-related transcription in myeloid models (Jeffries et al., 2024).

Biological Rationale

Iron is required for oxygen transport, mitochondrial metabolism, DNA synthesis, and hematopoietic-cell proliferation. Chronic transfusion can increase total-body iron because each transfused red-cell unit supplies iron that the body cannot actively excrete. Excess iron can deposit in organs and can promote iron-mediated oxidative injury. These facts provide the biological rationale for iron chelation research in transfusion-dependent beta-thalassemia and other chronic anemias.

Deferasirox is an oral iron chelator used clinically to reduce chronic iron overload. The reference article describes deferasirox as effective for iron overload and notes its use in transfusion-dependent patients with myelodysplastic syndrome and other hematologic disorders (Jeffries et al., 2024). In this context, Exjade refers to a marketed name associated with deferasirox. The A3355 item is labeled Deferasirox Fe3+ chelate or Exjade Fe3+ chelate, which denotes a ferric complex rather than automatically establishing equivalence to the free active drug used in an oral formulation.

This distinction matters for beta-thalassemia iron chelation studies and chronic anemia iron management experiments. A study that asks whether free deferasirox removes labile iron is not identical to a study that exposes cells to a preformed deferasirox–Fe3+ species. The two preparations can differ in free-iron availability, transport, precipitation behavior, and cellular exposure. Those variables should be measured rather than assumed.

Mechanism of Action of Deferasirox Fe3+ chelate

Uncomplexed deferasirox acts as a ligand for ferric iron. Its iron chelation mechanism involves coordination of Fe3+ by donor atoms within the deferasirox structure. Chelation can lower the pool of chemically available iron and can facilitate iron elimination in the clinical setting. The present product is already described as an Fe3+ chelate. Therefore, it should be interpreted as a defined ferric coordination species for research, not simply as a source of free deferasirox.

The supplied chemical identity contains an oxidophenyl-rich deferasirox framework and an iron(3+) component. The listed molecular weight is 426.18 g/mol for the product species described by the vendor. The product page reports CAS 554435-83-5 and identifies Exjade Fe3+ chelate as a synonym (product information).

The reference study adds a cellular mechanism for uncomplexed deferasirox exposure. In murine and human myeloid systems, the effect of deferasirox varied with differentiation stage. The study measured mitochondrial reactive oxygen species, respiratory capacity, and transcriptional responses. Deferasirox produced a greater mitochondrial ROS increase in neutrophils than in progenitor cells. Hypoxic culture reduced this ROS accumulation in neutrophils. These findings show that oxygen tension and maturation state can modify an iron chelator response (Jeffries et al., 2024).

Single-cell transcriptomic analysis in the same study found reduced NF-κB and MYC target expression in progenitors and reduced PU.1, also called SPI1, target expression in neutrophils. The authors interpreted the combined results as evidence that deferasirox can impair terminal maturation of band neutrophils in the tested models. This cellular result should not be transferred directly to the preformed A3355 chelate without a matched experiment using the same exposure, solvent, oxygen condition, and cell system.

Evidence & Benchmarks

The following claims separate product specifications from findings reported for uncomplexed deferasirox in the peer-reviewed study.

1. Deferasirox is described as an oral iron chelator that is effective in the treatment of iron overload (Jeffries et al., 2024; DOI: 10.1111/bjh.19782)
2. Prior studies summarized in the reference article reported improved erythropoiesis in approximately 22% of transfusion-dependent patients with myelodysplastic syndrome; this percentage refers to clinical observations cited by the article, not to an A3355 assay (Jeffries et al., 2024; DOI: 10.1111/bjh.19782)
3. Deferasirox responses differed across myeloid differentiation stages in the murine and human model systems tested (Jeffries et al., 2024; DOI: 10.1111/bjh.19782)
4. Deferasirox increased mitochondrial ROS more strongly in neutrophils than in progenitor cells, and hypoxic culture mitigated the neutrophil ROS response (Jeffries et al., 2024; DOI: 10.1111/bjh.19782)
5. Single-cell transcriptomics associated deferasirox exposure with reduced NF-κB and MYC target expression in progenitors and reduced PU.1 target expression in neutrophils (Jeffries et al., 2024; DOI: 10.1111/bjh.19782)
6. The A3355 product is listed with a molecular weight of 426.18 g/mol, CAS 554435-83-5, and 98.00% purity; the vendor does not provide the analytical method or test conditions in the supplied dossier (A3355 product information)

Applications, Limits & Misconceptions

Deferasirox Fe3+ chelate can support controlled research on ferric coordination, iron-dependent cellular stress, and assay behavior of a preformed metal complex. It is particularly relevant when the experimental question concerns the chemical or biological consequences of an Fe3+-loaded deferasirox species. It can also serve as a comparator in studies that separately test free deferasirox, although the comparison requires verified identity and solvent matching.

The product is reported to dissolve in DMSO at at least 53.5 mg/mL and in ethanol at at least 12.68 mg/mL under vendor-reported conditions that are not specified in the dossier. It is described as insoluble in water. These values are planning benchmarks, not guarantees for every lot, temperature, mixing time, or assay buffer. Researchers should confirm clear-solution formation at the actual working concentration and temperature.

The Deferasirox Fe3+ Chelate: Assay Workflow Guide emphasizes identity confirmation, solvent controls, precipitation checks, and the distinction between free deferasirox and a preformed ferric complex. This article extends that workflow by connecting the chemical distinction to differentiation-stage-dependent findings from the 2024 myeloid study.

The Deferasirox Fe3+ Chelate: Protocols & Troubleshooting in Iron Overload Research focuses on practical assay troubleshooting. This article clarifies the translational boundary: an in-vitro exposure to A3355 does not reproduce oral pharmacokinetics, clinical dosing, or patient-level iron removal.

Common Pitfalls or Misconceptions

• It is not automatically free deferasirox. A preformed Fe3+ chelate should not be assumed to have the same unoccupied iron-binding capacity, uptake, or intracellular activity as uncomplexed deferasirox.
• It is not a water-compatible stock reagent. The product information describes water insolubility, so direct dilution into aqueous medium can produce precipitation or an uncontrolled delivered dose.
• It is not a clinical medicine. The A3355 material is labeled for scientific research use only and must not be used for diagnosis, treatment, or patient administration.
• It is not a universal ROS probe. The reference study found context-dependent responses that varied with myeloid maturation and oxygen conditions. A ROS change cannot be assigned to iron removal alone without appropriate controls.
• It is not evidence of clinical benefit in every anemia. The approximately 22% erythropoietic response summarized in the reference article applies to selected prior MDS observations and does not validate the product for chronic anemia treatment.

Workflow Integration & Parameters

A reproducible iron overload treatment research workflow should begin with chemical identity, solvent compatibility, and exposure verification. Treat A3355 as a preformed ferric species unless an analytical test establishes another composition. Record lot, purity statement, solvent, preparation time, storage history, cell type, differentiation state, oxygen condition, and endpoint.

Protocol Parameters

• Identity confirmation: Verify the product name, CAS 554435-83-5, listed formula description, and molecular weight of 426.18 g/mol against the vendor record before comparing it with free deferasirox.
• Solid storage: Store the material at -20 °C, as recommended in the product information. Protect repeated-use portions from unnecessary temperature cycling.
• Stock solvent: Use DMSO or ethanol only after confirming compatibility with the downstream assay. The vendor reports solubility of at least 53.5 mg/mL in DMSO and at least 12.68 mg/mL in ethanol under conditions not specified in the dossier.
• Aqueous dilution: Do not presume that a water-based stock will remain clear. Add the organic stock gradually to the assay medium with matched vehicle controls, then inspect for visible precipitation at the assay temperature.
• Solution handling: Prepare solutions close to the experiment and use them promptly. Long-term storage of solutions is not recommended by the product information.
• Vehicle control: Match the final DMSO or ethanol fraction across treated and control wells. Keep the vehicle fraction low enough for the biological system and validate vehicle tolerance independently.
• Free-drug comparator: If the hypothesis concerns the iron chelation mechanism of uncomplexed deferasirox, include a separately sourced free-deferasirox comparator rather than inferring free-drug activity from A3355.
• Biological context: For myeloid experiments, record differentiation stage and oxygen condition because the reference study reported different mitochondrial ROS and transcriptional responses in progenitors and neutrophils.
• Readout controls: Pair viability or differentiation measurements with a precipitation check and, where relevant, an iron-availability assay. A reduced signal can arise from insoluble material, solvent stress, altered iron availability, or a true cellular response.

The product page reports 98.00% purity, but purity does not establish aqueous stability, cellular uptake, or equivalence to a pharmaceutical formulation. Those properties require assay-specific validation. The most informative design is usually a matrix that separates chemical form, solvent, iron availability, oxygen condition, and cell maturation state.

Conclusion & Outlook

Deferasirox Fe3+ chelate is a research reagent for studying a ferric deferasirox complex. Its reported identity, organic-solvent solubility, water insolubility, -20 °C storage recommendation, and research-use-only status define the practical boundaries of A3355. The 2024 reference study shows that uncomplexed deferasirox can influence mitochondrial ROS, NF-κB-related transcription, MYC targets, and PU.1 targets in a differentiation- and oxygen-dependent manner. A key future experiment is a direct, matched comparison of the preformed Fe3+ chelate with free deferasirox under identical cellular conditions. That comparison would test, rather than assume, whether the two chemical forms produce overlapping biological responses.